There is a clinical unmet need to develop a safe more natural solution for reducing the LDL cholesterol and triglyceride levels without the side effects of currently available therapies.

CANNALEAN aims to address this unmet need by using a novel formulation of a synthetic form of Cannabidiol (CBD), a non-psychotropic component of Cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to significantly reduce lipid blood levels.

Low intestinal absorption is a major problem with oral CBD administration. The chitosan particle acts as a solvent of the CBD allowing better interaction with the intestinal cells membrane and higher absorption. The improved absorption allows lowering of the required dose to achieve an effect.

In addition, venous drainage from the intestine allows direct effect on the liver to decrease cholesterol synthesis.

Preliminary results show the effect of the novel formulation on cholesterol and triglycerides reduction cholesterol and triglycerides reduction:

Our preliminary in vivo results in Guinea pig and rat models show the effect of the novel formulation on cholesterol and triglycerides reduction, as compared to controls and each compound alone.

The figures depict the results in a recent rat model study.
Cholesterol and triglyceride levels were significantly reduced following 2 periods of high fat / high sugar (HF/HS) diet to induce high lipid levels.

In addition, the Cholesterol/HDL ratio, as well as the triglycerides/ HDL ratio, which is thought to predict extensive coronary disease (Lemos de Luz et al, 2008) were also decreased.